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We read with interest the article by Tamimi and coworkers
recently published in this journal [1]. The authors compared
the molecular subtypes of invasive carcinoma versus ductal
carcinoma  in situ and found significant differences, as
expected [1]. However, we have some concerns regarding
the criteria used in the study.
First, the authors classified estrogen receptor (ER)-positive/
human epidermal growth factor receptor (HER)2-positive
tumors as luminal B (LUMB). Although this classification is in
accordance with that used in the Carolina Breast Cancer
Study [2], the LUMB tumors - as identified by gene
expression profiling - were all negative for HER2 [3]. The
LUMB tumors are defined as tumors that show low to
moderate expression of luminal specific genes, including the
ER cluster [3,4]. Extrapolating these findings to routine
practical use, one must use semiquantitative immunohisto-
chemistry (Allred-score, Q-score, or an H-score like method)
[5-8] to define and distinguish luminal A (LUMA) and LUMB
tumors. A large amount of information is lost when one labels
a tumor as a mere ER-positive one, because a tumor in which
15% of cells exhibit weak ER staining is biologically different
from one that demonstrates strong intensity staining in about
90% of cells. Although the vast majority of ER-positive tumors
show strong immunoreactivity, approximately 20% of tumors
exhibit variable ER expression. ER expression in breast
carcinoma is a continuous variable, which has been
demonstrated not only by immunohistochemistry and ligand
binding assay, but also by quantitative RT-PCR assays [6,9-
11]. Moreover, using data from the NSABP B-14 clinical trial,
Baehner and coworkers [12] demonstrated that the greater
benefit from tamoxifen is seen in patients with greater ER
expression, as determined by RT-PCR.
Although it is difficult to define a cut-off, any ER-positive/
HER2-negative tumor showing diffuse and strong ER
expression in two-thirds of the tumor (an H-score of 200 or
higher) could be considered to be a LUMA tumor and the
remainder of ER-positive/HER2-negative tumors could be
considered LUMB. Although not the most accurate, this
arbitrary cut-off is simple and keeps the category of LUMA
tumors as pure as possible using immunohistochemistry. The
ER-positive/HER2-positive tumors could similarly be
subdivided into LUMA-HER2 hybrid (LAHH) and LUMB-
HER2 hybrid (LBHH), based on ER expression levels. The
LBHH tumors probably correspond to the originally
described luminal C tumors [3]. LAHH tumors definitely exist
but do not have a molecular correlate. We believe that this
distinction is necessary before studies utilizing surrogate
immunohistochemical markers are undertaken, because
HER2-positive tumors should be separated from pure luminal
tumors, which should be further categorized as LUMA and
LUMB tumors.
Second, the authors considered HER2 2+ expression by
immunohistochemistry to be a positive finding. Numerous
studies have shown that only one-quarter of
immunohistochemical score 2+ cases demonstrate HER2
gene amplification by fluorescence in situ hybridization [13].
The authors did mention that ‘the results of analyses in which
HER2 positivity was defined as 3+ were very similar to those
presented with a definition of 2+ and 3+’. However, the more
important question is about the comparison of ‘2+ only’
cases with ‘3+ only’ cases.
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